Breast Cancer, Circulating Tumor DNA, HER2-positive Breast Cancer, Neoadjuvant
Conditions
Keywords
breast cancer, circulating tumor DNA, MRD
Brief summary
1. To explore the predictive value of ctDNA in HER2 positive breast cancer neoadjuvant therapy population; 2. To evaluate the prognostic value of ctDNA in HER2 positive breast cancer neoadjuvant therapy population.
Detailed description
This study plans to enroll 50 HER2 positive breast cancer patients in early stage (T2-3, N0-1, M0)/local late stage (T2-3, N2-3, M0 or T4a-c, Nany, M0), collect baseline tumor tissue samples of patients, as well as peripheral blood samples of multiple nodes at baseline, during new adjuvant therapy, after new adjuvant therapy (before surgery), and after surgery, detect the mutation of tumor tissue through 1021 panel, and conduct ctDNA detection of peripheral blood samples based on personalized panel design based on tumor tissue specific mutations, to explore the efficacy prediction and prognostic predictive value of ctDNA in HER2 positive new adjuvant therapy population.
Interventions
DIAGNOSTIC_TESTctDNA-MRD
This study is an observational non intervention study that only tests peripheral blood samples from different treatment nodes of the subjects, without interfering with the normal clinical diagnosis and treatment process of the patients.
Sponsors
The First Affiliated Hospital with Nanjing Medical University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Women with breast cancer diagnosed clinically and pathologically, aged 18-75 years; 2. ECOG performance score is 0-1; 3. Histologically confirmed as early or locally advanced invasive breast cancer: the diameter of the primary tumor is more than 2 cm, and HER2 is positive (confirmed by IHC or FISH). 4. The patient did not receive any treatment for breast cancer before enrollment; 5. Having lesions measurable according to RECIST 1.1 standards; 6. The subjects voluntarily joined this study, signed an informed consent form, had good compliance, and cooperated with follow-up; 7) Breast cancer patients who plan to use neoadjuvant therapy.
Exclusion criteria
1. Patients with known metastatic or stage IV breast cancer; 2. There are other untreated malignant tumors other than breast cancer; 3. Patients with one or more serious systemic diseases that, in the eyes of researchers, can impair their ability to complete research; 4. According to the researchers' assessment, there may be other factors that could force the subjects to terminate the study midway, such as suffering from other serious illnesses (including mental illnesses) that require concurrent treatment, severe abnormal laboratory test values, family or social factors, which may affect the safety of the subjects or the collection of experimental data. 5. Unable to follow up with the study according to the determined clinical follow-up period; 6. Cannot accept or provide specified efficacy evaluation methods such as CT. 7. Unable to obtain sufficient tumor tissue samples or peripheral blood samples.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Postoperative pathological pCR rate | 2024.3 -- 2026. 3 | Postoperative pathological pCR rate of HER-2 positive breast cancer patients after completing neoadjuvant therapy and undergoing surgical resection |
Countries
China
Contacts
Primary ContactZhihone Zhang, Doctor of Medicine
Backup ContactJing Wu, Doctor of Medicine
Outcome results
None listed